Concise review: Adult multipotent stromal cells and cancer: Risk or benefit?

被引:194
作者
Lazennec, Gwendal [1 ,2 ]
Jorgensen, Christian [1 ,2 ]
机构
[1] INSERM, U844, F-34091 Montpellier 5, France
[2] Univ Montpellier I, Montpellier, France
关键词
multipotent stromal cells; mesenchymal stem cells; cellular therapy; cancer; cellular proliferation; angiogenesis; chemokines;
D O I
10.1634/stemcells.2007-1006
中图分类号
Q813 [细胞工程];
学科分类号
摘要
stromal cells (MSCs) and carcinoma and the possible use of MSCs in cell-based anticancer therapies. MSCs are present in multiple tissues and are defined as cells displaying the ability to differentiate in multiple lineages, including chondrocytes, osteoblasts, and adipocytes. Recent evidence also suggests that they could play a role in the progression of carcinogenesis and that MSCs could migrate toward primary tumors and metastatic sites. It is possible that MSCs could also be involved in the early stages of carcinogenesis through spontaneous transformation. In addition, it is thought that MSCs can modulate tumor growth and metastasis, although this issue remains controversial and not well understood. The immunosuppressive properties and proangiogenic properties of MSCs account, at least in part, for their effects on cancer development. On the other hand, cancer cells also have the ability to enhance MSC migration. This complex dialog between MSCs and cancer cells is certainly critical for the outcome of tumor development. Interestingly, several studies have shown that MSCs engineered to express antitumor factors could be an innovative choice as a cell-mediated gene therapy to counteract tumor growth. More evidence will be needed to understand how MSCs positively or negatively modulate carcinogenesis and to evaluate the safety of MSC use in cell-mediated gene strategies.
引用
收藏
页码:1387 / 1394
页数:8
相关论文
共 94 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Chemokines: novel targets for breast cancer metastasis [J].
Ali, Simi ;
Lazennec, Gwendal .
CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) :401-420
[3]  
Angoulvant D, 2004, BIORHEOLOGY, V41, P469
[4]   Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma [J].
Arnulf, B. ;
Lecourt, S. ;
Soulier, J. ;
Ternaux, B. ;
Lacassagne, M-Noelle ;
Crinquette, A. ;
Dessoly, J. ;
Sciaini, A-K ;
Benbunan, M. ;
Chomienne, C. ;
Fermand, J-P ;
Marolleau, J-P ;
Larghero, J. .
LEUKEMIA, 2007, 21 (01) :158-163
[5]   Biology of EWS/ETS fusions in Ewing's family tumors [J].
Arvand, A ;
Denny, CT .
ONCOGENE, 2001, 20 (40) :5747-5754
[6]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[7]   Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term In vitro culture and do not exhibit telomere maintenance mechanisms [J].
Bernardo, Maria Ester ;
Zaffaroni, Nadia ;
Novara, Francesca ;
Cometa, Angela Maria ;
Avanzini, Maria Antonietta ;
Moretta, Antonia ;
Montagna, Daniela ;
Maccario, Rita ;
Villa, Raffaella ;
Daidone, Maria Grazia ;
Zuffardi, Orsetta ;
Locatelli, Franco .
CANCER RESEARCH, 2007, 67 (19) :9142-9149
[8]  
Bhatia Rinky, 2005, Congest Heart Fail, V11, P87, DOI 10.1111/j.1527-5299.2005.03618.x
[9]   Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells [J].
Burns, JS ;
Abdallah, BM ;
Guldberg, P ;
Rygaard, J ;
Schroder, HD ;
Kassem, M .
CANCER RESEARCH, 2005, 65 (08) :3126-3135
[10]   Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow [J].
Campagnoli, C ;
Roberts, IAG ;
Kumar, S ;
Bennett, PR ;
Bellantuono, I ;
Fisk, NM .
BLOOD, 2001, 98 (08) :2396-2402